Table 2. Risk of severe thalassemia in fetus based on Hb analysis during January 2021 to April 2023 (n = 129).
| Risk of severe thalassemia in fetus | Parent I | Parent II | N (129) |
|---|---|---|---|
| Homozygous α0-thalassemia 89.15% (115/129) |
A2A | A2A | 55 |
| EE | A2A | 26 | |
| EA (Hb E<25%) | A2A | 10 | |
| A2A | A2A (Hb A2>3.5%) | 9 | |
| EE | EA<25% | 3 | |
| A2A | A2ABart’sH | 3 | |
| CSEA (Hb E<25%) | A2A | 3 | |
| A2A | A2FA | 2 | |
| EE | EE | 1 | |
| EE | CSEA (Hb E<25%) | 1 | |
| EE | EFA | 1 | |
| EA (Hb E<25%) | CSEA (Hb E<25%) | 1 | |
| Homozygous α0-thalassemia and Homozygous β0-thalassemia 0.78% (1/129) |
A2A (Hb A2>3.5%) | A2A (Hb A2>3.5%) | 1 |
| Homozygous α0-thalassemia and Compound heterozygous β0-thalassemia /Hb E 2.33% (3/129) |
EA (Hb E<25%) | A2A (Hb A2>3.5%) | 1 |
| EE | A2A (Hb A2>3.5%) | 1 | |
| EA (Hb E<25%) | EE/EF | 1 | |
| Compound heterozygous β0-thalassemia/Hb E 7.75% (10/129) |
EA (Hb E>25%) | EF | 1 |
| EA (Hb E>25%) | EE/EF | 1 | |
| CSEA (Hb E>25%) | EE/EF | 1 | |
| EA (Hb E>25%) | A2A (Hb A2>3.5%) | 6 | |
| A2A (Hb A2>3.5%) | EA (Hb E>25%) | 1 |